Show results for
Refine by
Preclinical Modeling Suppliers Serving Norway
31 companies found
based inMontreal, QUEBEC (CANADA)
SCIREQ strives to make a strong impact on global pulmonary health by empowering scientists to better understand and eradicate lung diseases. The global burden of respiratory diseases is primarily driven by asthma, chronic obstructive pulmonary ...
Surgical skills are needed for all our implanted telemetry and for some in vitro isolated organs ...
based inAnkara, TURKEY
Nisan Medical is successfully operating in the industry for almost 30 years. They are especially creating turnkey hospital projects all around Turkey and operate the application. They work with key business partners for Central Sterilization Units ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
Neuromyelitis optica (NMO) is an neurological autoimmune condition classified as a rare disease. Because of this classification, NMO lacks effective treatment options, since it is not of primary interest to the pharmaceutical industry. However, ...
based inBerlin, GERMANY
Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: developing precision medicine to rescue vascular integrity and saving the lives of critically ill patients with limited treatment options. The ...
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
The Modi-2 vaccine exploits a second post-translational modification, stimulating the production of CD4 T cells using tumour-associated peptide epitopes in which the lysine residues are converted to homocitrulline. This change occurs via a process ...
based inBillerica, MASSACHUSETTS (USA)
Access Vascular is offering a suite of vascular access devices that use our novel, patented biomaterial featuring MIMIX™ technology which is designed to prevent the most common and costly complications in vascular access. Keep treatment moving ...
based inBoston, MASSACHUSETTS (USA)
At Emulate, we understand that animal studies and reductionist models are limited because they are not based on integrated human biology. By leveraging 21st century technologies, we are able to overcome these limitations with living human in vitro ...
Investigate mechanisms of colon inflammation and barrier disruption and evaluate the efficacy of anti-inflammatory drug candidates in an organoid-derived ...
based inUnion City, CALIFORNIA (USA)
Fibralign is an award-winning, commercial-stage, Stanford-spinout that designs, develops and produces novel therapeutic medical devices to address major unmet medical needs. Based in the San Francisco Bay Area, the company’s team has established GMP ...
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means ...
based inBelgrade, MONTANA (USA)
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, ...
OsteoSelect was engineered for superior performance. The graft does not adhere to gloves yet maintains its placement in the surgical environment. Osteoinductivity of sterile final product is assessed in vivo. In this challenging model, every lot ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
INM-088 is a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (API) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide ...
based inSeattle, WASHINGTON (USA)
Nexelis is your partner for assay and biomarker development, advanced bioanalytical and laboratory testing, and translational immunology. As the leading specialty laboratory, we have unrivaled expertise in immunology, specifically in the areas of ...
based inDiepenbeek, BELGIUM
Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug ...
We offer multi-validation solutions for preclinical targets across numerous therapeutic fields. ...
based inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
based inHerzliya, ISRAEL
elminda was founded in 2006 with the goal of addressing the unmet needs of people suffering from brain related disorders. Our mission: perfect a technology that would reveal an individual’s unique brain function “signatures” or “fingerprints,” ...
CNS drugs exhibit the lowest approval success rates due to multiple challenges such as lack of efficacy in early and advanced stages of development, Poor target selection / engagement, poor translation from pre-clinical models and disease ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a ...
based inCambridge, UNITED KINGDOM
We’re driven by the shared purpose of breaking new ground in the discovery of new treatments for rare diseases. Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to ...
Our Rare Treatment Accelerator helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
The human lung is a key organ for multiple therapeutic endpoints, as well as a system that must be evaluated for potential drug-induced toxicities to ensure safety. Modeling the complex interplay of respiratory and vascular ...
based inHeerlen, NETHERLANDS
DSM is a global purpose-led, science-based company specializing in Nutrition, Health & Sustainable Living. Our purpose is to create brighter lives for all. We achieve it by using all the scientific and innovation power at our disposal to tackle some ...
Discover our implantable drug delivery systems made of bioresorbable polymers that release precise quantities of therapeutic agents gradually over time. DSM is a global leader in biomedical materials science – experience that we are now using ...
based inKøbenhavn N, DENMARK
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant ...